Page 43 - Read Online

Pavan et al. J Transl Genet Genom 2021;5:173-81 https://dx.doi.org/10.20517/jtgg.2021.18 Page 175

Table 1. Summary of studies
Number
Year of Control Diagnostic Prognostic Tissue
Ref. of Cases Sample Methodology Biomarker Specificity Sensitivity
publication patients group value value concordance
Reis et al. [11] 2015 82 34 PCa 48 Serum Ms-SNuPE and GADD45a Yes Yes No 87% 94%
healthy pyrosequencing
control
[10]
Haldrup et al. 2018 815 705 110 Serum MS-qPCR ST6GALNAC3, Yes Yes Yes 100% 67%
PCa/ZNF660 healthy ZNF660, HAPLN3
tested in control
different
cohorts
[13]
Menschikowski et al. 2018 2 2 PCa NA Serum OBBPA-ddPCR PLA2R1 Yes No No NA NA
Brikun et al. [5] 2018 94 42 PCa 52 Urine (after MS-qPCR by binary ADCY4, AOX1rc, Yes No No 71% after 89% after
healthy DRE and at presence (> 0) or APC, CXCL14, DRE and FV DRE and
control FV) absence (< 0) of EPHX3, GFRA2, 94% from
methylation GSTP1, HEMK1rc, FV
KIFC2, MOXD1,
HOXA7, HOXB5,
HOXD3, HOXD9,
HOXD10, HOXD3a,
HOXD3b,
NEUROG3,
NODAL, RASSF5
Brikun et al. [4] 2019 94 42 PCa 52 Urine (85 MS-qPCR by binary PANEL ABOVE Yes No No 76% from 81% from
healthy after DRE and presence (> 0) or PLUS 13 additional DRE-77% DRE-93%
control 65 at FV) absence (< 0) of markers: after FV after FV
methylation HOXA11as, KLK10,
GPR147, GPR62,
HOXD4rc,
HOXD3c, FRZB,
GRASPrc,
HOXBAS3,
HOXD8rc, RASSF1,
SLC16A5rc
[6]
Nekrasov et al. 2019 64 31 PCa 33 Urine qMSP APC2, CDH1, Yes Yes No 100% 78%
healthy FOXP1, FOXP2,
control FOXP3, FOXP4,
H1C1, HOXA9,
LRRC3B, MGMT,
NDRG4, PLCL2,
PTEN, UBE2E2,
VHL, WNT7A,
ZIC4
[16]
O’Reilly et al. 2019 463 209 PCa/31 + 254 Urine HumanMethylation450 Methylation array Yes Yes Yes 76% 73%